- Fusion Pharmaceuticals (NASDAQ:FUSN) will collaborate with AstraZeneca (NASDAQ:AZN) to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for cancer.
- The partnership will leverage Fusion's Targeted Alpha Therapies (TATs) platform and know-how in radiopharmaceuticals with AstraZeneca's portfolio of antibodies and cancer therapeutics, including DNA damage response inhibitors.
- Under the terms of the deal, the parties will discover, develop and commercialize novel TATs based on Fusion's Fast-Clear linker technology with AZN's oncology antibodies. In addition, they will explore certain combo strategies between TATs, including Fusion's lead candidate FPI-1434, and AZN's therapeutics for the potential treatment of a range of cancers. Both companies will retain full rights to their respective assets.
- AZN will pay fusion an upfront fee, milestones and other payments. Specific financial terms remain confidential.
- Fusion will host a conference call this morning at 8:30 am ET to discuss the collaboration.
- https://seekingalpha.com/news/3629545-fusion-pharma-teams-up-astrazeneca-in-next-gen-radiopharmaceuticals-for-cancer
Monday, November 2, 2020
Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.